Patents Assigned to Stem Cell Therapeutics Inc.
-
Publication number: 20120329714Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: ApplicationFiled: June 28, 2012Publication date: December 27, 2012Applicant: STEM CELL THERAPEUTICS INC.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20120189575Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.Type: ApplicationFiled: March 19, 2012Publication date: July 26, 2012Applicant: Stem Cell Therapeutics Inc.Inventor: Samuel Weiss
-
Patent number: 8222212Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: GrantFiled: December 29, 2010Date of Patent: July 17, 2012Assignee: Stem Cell Therapeutics Inc.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20110269681Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: ApplicationFiled: December 29, 2010Publication date: November 3, 2011Applicant: STEM CELL THERAPEUTICS INC.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20110182853Abstract: The present invention is related to the discovery of a novel class of neural progenitor cells, which proliferate in response to platelet derived growth factor (PDGF) and differentiate into neurons and oligodendrocytes but not astrocytes. Progeny of the progenitor cells can be obtained by culturing brain tissue in PDGF without serum, epidermal growth factor (EGF), fibroblast growth factor 2, or transforming growth factor alpha. Upon subculturing into EGF-containing media, these progeny cells can proliferate and form neurospheres, whereas PDGF has no such effect.Type: ApplicationFiled: April 7, 2011Publication date: July 28, 2011Applicant: STEM CELL THERAPEUTICS INC.Inventors: Samuel Weiss, Andrew K. Chojnacki
-
Patent number: 7884072Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: GrantFiled: March 19, 2008Date of Patent: February 8, 2011Assignee: Stem Cell Therapeutics Inc.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20100135968Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.Type: ApplicationFiled: February 2, 2010Publication date: June 3, 2010Applicant: Stem Cell Therapeutics Inc.Inventor: Samuel Weiss
-
Patent number: 7704737Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.Type: GrantFiled: July 30, 2003Date of Patent: April 27, 2010Assignee: Stem Cell Therapeutics Inc.Inventor: Samuel Weiss
-
Publication number: 20090274668Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.Type: ApplicationFiled: July 16, 2009Publication date: November 5, 2009Applicant: Stem Cell Therapeutics IncInventors: Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo
-
Patent number: 7604993Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.Type: GrantFiled: January 30, 2006Date of Patent: October 20, 2009Assignee: Stem Cell Therapeutics Inc.Inventors: Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo
-
Publication number: 20080181873Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: ApplicationFiled: March 19, 2008Publication date: July 31, 2008Applicant: STEM CELL THERAPEUTICS INC.Inventors: Tetsuro Shingo, Samuel Weiss
-
Patent number: 7393830Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: GrantFiled: August 30, 2002Date of Patent: July 1, 2008Assignee: Stem Cell Therapeutics Inc.Inventors: Tetsuro Shingo, Samuel Weiss
-
Patent number: 7368115Abstract: The present invention relates to a method of increasing the number and/or differentiation of neural stem cells and/or neural stem cell progeny using pituitary adenylate cyclase-activating polypetide (PACAP). In a preferred embodiment, additional growth factors are also utilized. The present invention can be practiced in vivo and in vitro, rendering it useful for the treatment of neurodegenerative disease and other neural trauma.Type: GrantFiled: July 31, 2003Date of Patent: May 6, 2008Assignee: Stem Cell Therapeutics Inc.Inventors: Shigeki Ohta, Samuel Weiss
-
Publication number: 20070179092Abstract: The present invention relates to a method of increasing the number and/or differentiation of neural stem cells and/or neural stem cell progeny using pituitary adenylate cyclase-activating polypeptide (PACAP). In a preferred embodiment, additional growth factors are also utilized. The present invention can be practiced in vivo and in vitro, rendering it useful for the treatment of neurodegenerative disease and other neural trauma.Type: ApplicationFiled: January 24, 2007Publication date: August 2, 2007Applicant: STEM CELL THERAPEUTICS INC.Inventors: Shigeki Ohta, Samuel Weiss
-
Publication number: 20070111932Abstract: Methods are described for the enhancement and/or induction of migration of neural stem cells or neuronal progenitor cells. Multipotent neural stem cells are exposed to erythropoietin which enhances the migration of multipotent neural stem cells and neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin. In a preferred embodiment, additional growth factors, such as EGF and prolactin, are utilized.Type: ApplicationFiled: July 31, 2003Publication date: May 17, 2007Applicant: Stem Cell Therapeutics Inc.Inventor: Linda Andersen
-
Publication number: 20060148084Abstract: The present invention provides a method of increasing neural stem cell numbers by using growth hormone and/or IGF-1. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions.Type: ApplicationFiled: March 1, 2006Publication date: July 6, 2006Applicant: Stem Cell Therapeutics Inc.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20060121007Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.Type: ApplicationFiled: January 30, 2006Publication date: June 8, 2006Applicant: Stem Cell Therapeutics Inc.Inventors: Bradley Thompson, Samuel Weiss, Tetsuro Shingo
-
Patent number: 7048934Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.Type: GrantFiled: August 30, 2002Date of Patent: May 23, 2006Assignee: Stem Cell Therapeutics Inc.Inventors: Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo
-
Patent number: 7033995Abstract: The present invention relates to a method of producing radial glial cells from neural stem cells, particularly by contacting neural stem cells with epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2) and/or TGF?. Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) can optionally be added to enhance the effect of EGF, FGF-1 or TGF?. Also provided are methods of producing radial glial cells from ependymal cells, as well as methods of proliferating ependymal cells.Type: GrantFiled: July 17, 2002Date of Patent: April 25, 2006Assignee: Stem Cell Therapeutics Inc.Inventors: Samuel Weiss, Christopher Gregg
-
Publication number: 20050148071Abstract: The present invention relates to a method of producing neurons that express the enzyme tyrosine hydroxylase (TH) by subjecting neural stem cells to FGF-1, a protein kinase A activator, a protein kinase C activator, and dopamine/L-DOPA. Surprisingly, when forskolin is used as a protein kinase A activator, it requires only low levels of FGF-1 and forskolin to efficiently produce TH positive neurons from fetal or adult neural stem cells. Also provided are compositions used to produce TH positive neurons and the resulting neural cell culture, as well as a method of treating disease or conditions which are associated with dopamine neuron loss or dysfunction.Type: ApplicationFiled: November 10, 2004Publication date: July 7, 2005Applicant: Stem Cell Therapeutics Inc.Inventors: Samuel Weiss, Tetsuro Shingo